Enamel Matrix Derivative and Demineralized Freeze-Dried Bone Allograft in treatment of Class II furcation defect

Phase 2

Conditions: Health Condition 1: K053- Chronic periodontitis

Registration Number: CTRI/2023/08/056791

Lead Sponsor: Sardar Patel Post Graduate Institute of Dental and Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: ot Yet Recruiting

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

Patients willing for voluntary participation & have signed informed consent for the described procedure.

Systemically healthy patients (ASA I & II) with Periodontitis

Class II buccal furcation defects of horizontal component more than 3mm on clinical & radiographic evaluation

The sites should exhibit clinical evidence of PPD of more than 3mm and CAL of more than 2mm

Patients with established willingness and ability to perform adequate oral hygiene

Exclusion Criteria

1.Subjects who have received periodontal flap/regenerative therapy within the past 1 year

Patients who have received antibiotic therapy within the past six months

Pregnant and lactating patients

Smokers and tobacco chewers

Patients who demonstrate poor oral hygiene maintenance after Phase I therapy

Tooth with gingival recession exposing furcation, endodontic-pulpal

involvement, or mobility > Grade II

Systemic illness known to affect the outcomes of periodontal therapy; such as

uncontrolled diabetes mellitus, cardiac diseases, immune-compromised (e.g.,

HIV individuals, under radiotherapy), patients taking medications such as corticosteroids or calcium channel blockers, which are known to interfere with

periodontal wound healing

Patients with any known allergy to drugs

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The possible outcome of this study will be to see the improvement in Clinical Attachment Level and Bone forming capacity using Enamel Matrix Derivative in furcation defectsTimepoint: Baseline <br/ ><br>3 Months <br/ ><br>6 Months

Secondary Outcome Measures